AD Pipeline Watch: Sitryx Advances SYX-5219 to the Clinic
Sitryx Therapeutics plans to advance SYX-5219, an oral, targeted, disease-modifying anti-inflammatory therapy that targets pyruvate kinase M2 (PKM2), to the clinic. Modulation of PKM2 alters B and T lymphocyte function and represents a novel therapeutic target with the potential to rebalance the immune system, normalize immune cell function and drive sustained disease remission in AD. […]